Direct-acting antivirals (DAAs) are effective in treatment of hepatitis C virus (HCV) genotype 1 infection, but their cost and value have been debated. We performed a systematic review of published cost-effectiveness analyses of DAAs, synthesized their results with updated drug prices, and calculated the maximum price at which DAA therapy for HCV genotype 1 infection is cost-effective (increased quality-adjusted life-years [QALYs] and increased cost that the society is willing to pay) and cost-saving (increased QALYs and decreased costs).
See editorial on page 838. W orldwide, more than 170 million people are chronically infected with hepatitis C virus (HCV). 1 HCV infection is the leading cause of hepatocellular carcinoma and is the most common indication for liver transplantation in the United States and Europe. 2 Of the 6 HCV genotypes, genotype 1 is the most prevalent in the Western world and accounts for at least 70% of all chronic infections. 3 HCV treatment has rapidly evolved over the past few years beginning with the launch of 2 direct-acting antivirals (DAAs), boceprevir and telaprevir, in 2011 for genotype 1, followed by the availability of several new oral DAAs from 2013 onward, including sofosbuvir, simeprevir, ledipasvir, daclatasvir, and Viekira Pak. New oral therapies are superior, with efficacy greater than 95% in most patients, and require shorter duration of treatment and have fewer adverse effects than the older therapies.
However, the high price coupled with the high demand for oral DAAs has created concerns about their impact on health care budgets, delaying timely treatment to several HCV patients. The high price of these drugs has led to a national debate about the value and affordability of HCV treatment in the United States and elsewhere. Citing these concerns, several payers, including state Medicaid programs, have restricted these treatments to patients with advanced stages of hepatic fibrosis. 4 Cost-effectiveness analysis (CEA) can inform stakeholders regarding the value of HCV treatment and allow them to compare its value with other medical interventions. Using a decision-analytic modeling approach, such analysis can project the long-term health benefits of HCV treatment, predict long-term costs of HCV sequelae, and weigh them against the cost of up-front treatment.
Several CEAs using models of HCV were recently published that assessed the value of treatment by estimating the incremental cost-effectiveness ratios (ICERs), which provide the cost of gaining 1 additional quality-adjusted life-year (QALY). However, different modeling assumptions, including those regarding the costs of DAAs, may have influenced their results. Furthermore, drug prices have come down considerably after the publication of these cost-effectiveness studies, so their results are outdated and may not accurately depict the current real-world value. Our objective was 2-fold: to systematically review the published CEAs of DAAs and synthesize published results after updating their cost assumptions, and to estimate the threshold drug prices below which HCV treatment is cost-effective and/or cost-saving.
Methods
We synthetized the cost-effectiveness results by controlling for the drug price, HCV genotype, treatment history, and geographic region. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement to report our results.
Information Sources and Search
We conducted a literature search in general (ie, PubMed, Medline, EMBASE, The Cochrane library) and content-specific electronic databases (ie, EconLit, Database of Abstracts of Reviews of Effects, National Health Service Economic Evaluation Database and Health Technology Assessment database, Tufts CEA registry). The search covered peer-reviewed original articles published from January 1, 2011, until September 8, 2015 . The list of references from potentially relevant articles was also searched. All results were imported into a reference manager software and merged, and then duplicates were removed. Supplementary Table 1 shows the search strategy used for the Medline database.
Inclusion and Exclusion Criteria
We included any article that reported an economic model to estimate the cost-effectiveness of treating HCV patients with DAAs in comparison with old standard of care, which was dependent on the primary intervention and the target population. We included all approved DAAs categorized as first-generation and second-generation DAAs. The first-generation DAAs included boceprevir and telaprevir; and second-generation DAAs included simeprevir, paritaprevir, asunaprevir, ledipasvir, ombitasvir, sofosbuvir, daclatasvir, and dasabuvir. The comparators for first-generation DAAs were peginterferon-ribavirin or no treatment, and the comparators for second-generation DAAs were first-generation DAAs, peginterferonribavirin, or no treatment.
We excluded articles that were not published in English, not original studies (ie, reviews, opinion articles), did not provide modeling techniques used, did not report QALYs, reported only budget impact or cost-of-illness analysis, did not report any results for genotype 1 patients, reported a drug regimen that has not been approved by the Food and Drug Administration or recommended by a professional organization, did not report cost-effectiveness results compared with the old standard of care, did not report sensitivity analysis on the cost of HCV treatment, or only included patients coinfected with other viral infections (eg, human immunodeficiency virus, hepatitis B virus).
Study Selection
Two reviewers screened the titles and abstracts of the unique citations independently. The first step was to assess whether inclusion criteria were met. Any disagreements regarding whether or not a particular analysis fulfilled the initial inclusion criteria were resolved by discussion leading to consensus. We then retrieved the full text of those relevant citations and excluded unsuitable analyses according to our exclusion criteria, resulting in the final group of studies analyzed.
Data Collection Process and Data Items
We used a standardized extraction form to collect information. One reviewer abstracted data from the included studies and another reviewer crosschecked the abstracted information. We collected basic information regarding the study including study year; country for which the analysis was performed; drug regimen as primary intervention, which was further categorized as first-generation DAAs (boceprevir-and telaprevir-based therapies) and second-generation DAAs; and the comparator regimen. Additional information, such as characteristics of the modeled population including presence of cirrhosis, HCV genotype, and treatment experience, was extracted. Model features relevant to the cost-effectiveness of HCV treatment, such as perspective, discount rate, treatment-as-prevention benefits, extrahepatic benefits, and reinfection after sustained virologic response (SVR), were also noted.
Quality Appraisal
One investigator (T.H.) assessed the quality of reporting using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, 5 and another investigator (M.L.-O.) cross-checked the entries. The CHEERS statement is a 24-item checklist evaluating 6 sections of an economic evaluation. Each of the items was explicitly judged as follows: Yes ¼ "information reported" or No ¼ "information not reported." The quality of the included studies was reported as the number of missing information across studies per item and converted to percentages.
Synthesis of Results: Reanalysis of Incremental Cost-Effectiveness Ratios and Threshold Drug Price
To account for differences in treatment costs used by published studies, we recalculated each ICER at the wholesale acquisition cost of DAAs and over a range of $20,000-$100,000. We converted all costs to 2014 US dollar value using the Consumer Price Index for each country and the average currency conversion rate in 2014. 6, 7 Because treatment costs and ICERs have a linear relationship, we used the linear interpolation approach to find the ICER at any treatment cost. For that purpose, we first extracted all reported costs, QALYs, and ICERs from all studies. For each analysis, we also extracted an ICER at a different price either using the published 1-way sensitivity analysis or price-threshold analysis. If the sensitivity analysis on the cost of HCV treatment was not reported, we removed that ICER from our analysis. The following equation provides the ICER (denoted by ICER X ) when the price of DAAs is X:
where Price A and Price B along with their corresponding ICERs (ICER A and ICER B ) were extracted from the published studies.
For each study, we further estimated the threshold price below which treatment with DAAs would become cost-effective using the willingness-to-pay (WTP) threshold of $100,000-per-QALY and cost-saving (ie, WTP threshold of $0-per-QALY). The following equation provides the relationship between the threshold drug price and WTP:
Results
Our search yielded 304 records. After exclusion of duplicates and 2-step screening, 24 unique studies were included in our analysis (Figure 1 ).
Overview of Studies and Patient Characteristics
Twenty-four studies were included in the systematic review. Supplementary Table 2 provides an overview of the study characteristics. These studies evaluated 170 ICERs of 11 different drug combinations from 11 different countries (Supplementary Table 3 ). Among them, 81 ICERs evaluated first-generation DAAs as the primary intervention; 67 were compared with peginterferonribavirin and 14 with no treatment. Furthermore, 89 ICERs evaluated second-generation DAAs as the primary intervention; 67 were compared with the old standard-ofcare (peginterferon-ribavirin or first-generation DAAs) and 22 with no treatment. Table 1 summarizes key modeling features of the included studies.
Region
Among the selected studies, 110 ICERs (65%) were reported by 10 (42%) studies conducted in the United States, 51 (26%) ICERs by 12 (44%) studies in Europe, 7 (4%) ICERs by 1 (4%) study in Asia, and 2 (1%) ICERs by 1 (4%) study in Australia (Supplementary Table 4 ).
Treatment Strategies
The cost-effectiveness models evaluated the following DAAs as primary interventions: first-generation DAAs boceprevir or telaprevir, in combination with peginterferon and ribavirin; and second-generation DAAs consisting of sofosbuvir and/or simeprevir with peginterferon and ribavirin, and oral DAAs consisting of different combinations of sofosbuvir, ledipasvir, daclatasvir with or without ribavirin, and ombitasvir/paritaprevir/ritonavir with dasabuvir and/or ribavirin ( Figure 2 ).
Modeling Assumptions
We noted structural assumptions made by published studies that are important in the context of HCV modeling and could impact the cost-effectiveness results. With the exception of 1 study, 8 which used a societal perspective, all other studies used the payer's perspective. We found that none of the studies captured the benefits of HCV treatment in reducing HCV transmission (ie, treatment as prevention); no study considered extrahepatic benefits associated with HCV treatment; only 1 study considered indirect economic benefits resulting from HCV cure 8 ; and only 4 out of 24 studies [8] [9] [10] [11] modeled the possibility of reinfection after achieving SVR.
Quality of Reporting
Supplementary Figure 1 summarizes the percentage of studies adequately reporting (and not reporting) each CHEERS methodologic item evaluated. In 29% of the studies an adequate structured abstract according to CHEERS standards was not provided, 20% did not adequately describe target population and subgroups, and 54% did not adequately describe the population and methods used to elicit preferences for outcomes. In addition, 17% did not provide the methodologic approach used to estimate resource use, and 29% did not explore all characteristics of uncertainty associated with patient-level data or model parameters.
Incremental Cost-Effectiveness Ratios
We estimated the ICER of each reported analysis by varying the price of DAAs from $20,000 to $100,000 and summarized the results by plotting the percentage of analyses that would be cost-saving, cost-effective, and not cost-effective for a given drug price. Figure 3A shows the results of 81 ICERs reported for first-generation DAAs. For instance, at a $60,000 price for DAAs, 2% analyses found first-generation DAAs to be cost-saving, 91% were found to be cost-effective, and 7% were found to be not cost-effective. Similarly, Figure 3B summarizes the results of 89 ICERs reported for secondgeneration DAAs. At a $60,000 price for these DAAs, 71% of the analyses found them to be cost-saving, 22% found them cost-effective, and 7% of the analyses found them not cost-effective.
We further conducted a subgroup analysis of secondgeneration DAAs. The cost-effectiveness of DAAs was similar in treatment-naive versus -experienced patients ( Figure 4A and B) and patients with cirrhosis versus patients without cirrhosis ( Figure 4C and D) . However, results differed substantially in US versus non-US-based analyses ( Figure 4E and F) . All of the analyses that found HCV treatment not cost-effective evaluated a combination of simeprevir-sofosbuvir-ribavirin.
Threshold Drug Price
The price thresholds at which DAA regimens become cost-effective and cost-saving were substantially lower for first-generation therapies compared with secondgeneration therapies ( Figure 5 ). The median threshold price of the treatment at which first-generation and second-generation DAAs become cost-effective compared with the old standard-of-care was $120,100 (interquartile range [ We further conducted a subgroup analysis on secondgeneration DAAs ( Supplementary Figure 2A-C) . The media drug price of DAAs used in US and non-US studies was $84,000 and $55,800, respectively. The median threshold price of the treatment at which these DAAs become cost-effective was above $200,000 irrespective of patients' prior treatment history or presence of cirrhosis. Similarly, the threshold price of treatment at which DAAs become cost-saving was around $70,000 irrespective of patients' prior treatment history or presence of cirrhosis. However, the price thresholds were substantially different for US versus non-US studies. The median threshold price for DAA regimens to become cost-effective was $260,300 (IQR, $183,800-$369,600) in US studies and $161,000 (IQR, $0-$219,600) in non-US studies. The corresponding price at which they become cost-saving was $79,000 (IQR, $60,300-$110,000) in US studies in contrast to $15,000 (IQR, $0-$31,200) in non-US studies.
Sensitivity Analysis Using $50,000 Willingness-to-Pay Threshold
We also conducted a sensitivity analysis using a conservative WTP threshold of $50,000-per-QALY. We found that the median threshold price of DAA regimens to become cost-effective in first-generation and second-generation drugs decreased to $66,800 (IQR, $44,900-$100,500) and $156,600 (IQR, $98,700-$228,100), respectively. The corresponding threshold prices in US and non-US analyses were $167,200 (IQR, $114,300-$232,000) and $94,800 (IQR, $0-$114,900), respectively, which still remained substantially below the listed wholesale acquisition cost of the DAAs.
Discussion
The recent availability of DAAs is expected to dramatically impact the landscape of HCV burden. 12, 13 However, the cost of DAAs and the large number of patients with HCV infection have become a barrier to provision of timely treatment. Although the effective prices of oral DAAs have fallen substantially since their launch in late 2013, the results of published costeffectiveness models have not been updated to accurately estimate the current value of HCV treatment. To address this crucial but missing gap in evidence, we systematically analyzed the results of 24 studies of HCV genotype 1 presenting 170 ICERs of combinations of 11 drugs from 11 countries. We found that most of the modeling studies concluded that oral DAAs provide good value for money, and can also result in substantial economic savings at current discounts.
To our knowledge, our study is the first to synthesize the results of the published cost-effectiveness studies of HCV treatment in the era of DAAs. Previous studies limited their scope to the systematic review of modeling approaches of HCV models and did not evaluate or reanalyze the cost-effectiveness results.
14,15 Moreover, we used a novel approach to present the cost-effectiveness results by providing the percent of studies per ICER and controlling for the drug price, patient's HCV genotype, prior treatment history, disease severity, and the region of the analysis. The evidence from our study that included 24 modeling studies is stronger than the evidence from any individual CEA study.
Our study has some limitations, therefore our results should be interpreted with caution. First, our synthesis is limited by the reported information in the included studies. For this reason, we evaluated their quality of reporting using the CHEERS statement and found that most items were adequately reported with only 1 poorly reported area (methods used to derive preferences for outcomes) in half of the studies. Second, our results could not control for several other model inputs including quality of life weights, discount rate, and cost of health states, which could lead to heterogeneity in results. Third, the focus of our study was on the cost-effectiveness of HCV treatment using DAAs, so our analysis did not include modeling studies that evaluated the cost-effectiveness of HCV screening plus treatment. We observed that US-based studies found HCV treatments to be more cost-effective than non-US-based studies despite the fact that the price of DAAs was higher in the United States than outside the United States. The reason for such trend could be that the cost of managing HCV-associated sequelae is higher in the United States; therefore, the economic benefits of preventing advanced sequelae were higher in the United States.
We believe that the published modeling studies could have underestimated the value of HCV treatment because most studies did not consider the benefits of HCV treatment in preventing transmission, extrahepatic benefits resulting from HCV treatment, such as in reduction in the incidence of non-Hodgkin lymphoma. 16 Therefore, future modeling studies should consider the previously mentioned factors to evaluate a more precise value of HCV treatment with DAAs.
Our study reinforces the message that the widespread and unrestricted treatment of HCV is the optimal strategy from a public health and economic perspective. There is an unprecedented situation with the availability of DAAs, which are potentially cost-saving interventions but the upfront (or initial) budget impact to implement these interventions is large. Our study provides evidence suggesting that HCV treatment can result in cost-savings. To our knowledge, not many treatments have been shown to be cost-saving in the history of medicine. Hence, we would support additional resources allocated to increased access to HCV treatment, as has been the case with human immunodeficiency virus.
In conclusion, our systematic reanalysis of costeffectiveness studies found that HCV treatment with second-generation DAAs is highly cost-effective and could likely result in cost-savings at currently available discounts. Therefore, timely treatment with DAAs without restrictions for HCV should be a priority to improve public health. Supplementary Figure 1 . Summary of the reported items according to CHEERS checklist.
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Supplementary Figure 2 . Box plots showing the median threshold price, 25th quartile, and 75th quartile at which treatment with second-generation DAAs is cost-effective (using $100,000-per-QALY willingness-to-pay threshold) and cost-saving in (A) treatment-naive versus treatment-experienced patients, (B) patients with versus without cirrhosis, and (C) and US versus non-US studies. 
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